Anika Therapeutics | ANIK - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Abbott USD 299M 231M 2026-06
Agenus USD 14.67M 1.35M 2026-03
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Anika Therapeutics 183.47M 4.09M 2026-06
Arrowhead Research USD 24.56M 716K 2026-06
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Halozyme Therapeutics USD 5.59M 80K 2026-06
Heron Therapeutics USD 600K 100K 2024-12
Insmed USD 18.84M 1.24M 2026-06
Integra LifeSciences USD 22.99M 529K 2026-06
Intrexon USD 2K 5K 2024-06
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.55M 66K 2026-03
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
MacroGenics USD 4.89M 1.55M 2026-03
Merit Medical Systems USD 12.12M 5.59M 2026-06
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 287M 109M 2026-06
Smith & Nephew USD 69M 1000K 2025-12
Stryker USD 47.93B 1.64B 2026-06
Veracyte USD 2K 1000 2023-12
Xencor USD 7.35M 2.65M 2026-06
Zimmer Biomet Holdings USD 22.8B 22.73B 2026-06